Mitomycin C in pterygium treatment
Pterygium is a benign lesion usually growing from the nasal side of the conjunctiva onto the cornea. Most cases of pterygium does not cause problem or requires specific treatment. The exact cause of pterygium is not clear yet, but some factors are pointed as causes, being the most important the long...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2016-03-01
|
| Series: | International Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.cn/en_publish/2016/3/20160325.pdf |
| _version_ | 1811282297853313024 |
|---|---|
| author | Thiago Gonçalves dos Santos Martins Ana Luiza Fontes de Azevedo Costa Milton Ruiz Alves Roger Chammas Paulo Schor |
| author_facet | Thiago Gonçalves dos Santos Martins Ana Luiza Fontes de Azevedo Costa Milton Ruiz Alves Roger Chammas Paulo Schor |
| author_sort | Thiago Gonçalves dos Santos Martins |
| collection | DOAJ |
| description | Pterygium is a benign lesion usually growing from the nasal side of the conjunctiva onto the cornea. Most cases of pterygium does not cause problem or requires specific treatment. The exact cause of pterygium is not clear yet, but some factors are pointed as causes, being the most important the long-term ultraviolet ray exposure. Pterygium surgery is usually considered when there are symptoms that do not respond to conservative treatment. Recurrence is the main complication of the surgery, and much has been done to avoid it. Mitomycin C (MMC) has been used as a fibroblast proliferation inhibitor during the surgery to reduce the chance of recurrence of the pterygium. This review describes the use of MMC as an adjunctive, the optimal dosage, the duration of administration of MMC and possible complications, when used during, after and before the surgery. Most studies suggest that increased exposure (dose or duration) of MMC is associated with a lower recurrence, but with higher risks of complications. |
| first_indexed | 2024-04-13T01:50:04Z |
| format | Article |
| id | doaj.art-e438b2e8e78b4933b9cfba7fb1866740 |
| institution | Directory Open Access Journal |
| issn | 2222-3959 2227-4898 |
| language | English |
| last_indexed | 2024-04-13T01:50:04Z |
| publishDate | 2016-03-01 |
| publisher | Press of International Journal of Ophthalmology (IJO PRESS) |
| record_format | Article |
| series | International Journal of Ophthalmology |
| spelling | doaj.art-e438b2e8e78b4933b9cfba7fb18667402022-12-22T03:07:55ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982016-03-019346546810.18240/ijo.2016.03.25Mitomycin C in pterygium treatmentThiago Gonçalves dos Santos Martins0Ana Luiza Fontes de Azevedo Costa1Milton Ruiz Alves2Roger Chammas3Paulo Schor4Federal University of São Paulo (UNIFESP), São Paulo 04023062, BrazilUniversity of São Paulo (USP), São Paulo 01246903, BrazilUniversity of São Paulo (USP), São Paulo 01246903, BrazilUniversity of São Paulo (USP), São Paulo 01246903, BrazilFederal University of São Paulo (UNIFESP), São Paulo 04023062, BrazilPterygium is a benign lesion usually growing from the nasal side of the conjunctiva onto the cornea. Most cases of pterygium does not cause problem or requires specific treatment. The exact cause of pterygium is not clear yet, but some factors are pointed as causes, being the most important the long-term ultraviolet ray exposure. Pterygium surgery is usually considered when there are symptoms that do not respond to conservative treatment. Recurrence is the main complication of the surgery, and much has been done to avoid it. Mitomycin C (MMC) has been used as a fibroblast proliferation inhibitor during the surgery to reduce the chance of recurrence of the pterygium. This review describes the use of MMC as an adjunctive, the optimal dosage, the duration of administration of MMC and possible complications, when used during, after and before the surgery. Most studies suggest that increased exposure (dose or duration) of MMC is associated with a lower recurrence, but with higher risks of complications.http://www.ijo.cn/en_publish/2016/3/20160325.pdfmitomycin Cpterygium surgeryrecurrence rate |
| spellingShingle | Thiago Gonçalves dos Santos Martins Ana Luiza Fontes de Azevedo Costa Milton Ruiz Alves Roger Chammas Paulo Schor Mitomycin C in pterygium treatment International Journal of Ophthalmology mitomycin C pterygium surgery recurrence rate |
| title | Mitomycin C in pterygium treatment |
| title_full | Mitomycin C in pterygium treatment |
| title_fullStr | Mitomycin C in pterygium treatment |
| title_full_unstemmed | Mitomycin C in pterygium treatment |
| title_short | Mitomycin C in pterygium treatment |
| title_sort | mitomycin c in pterygium treatment |
| topic | mitomycin C pterygium surgery recurrence rate |
| url | http://www.ijo.cn/en_publish/2016/3/20160325.pdf |
| work_keys_str_mv | AT thiagogoncalvesdossantosmartins mitomycincinpterygiumtreatment AT analuizafontesdeazevedocosta mitomycincinpterygiumtreatment AT miltonruizalves mitomycincinpterygiumtreatment AT rogerchammas mitomycincinpterygiumtreatment AT pauloschor mitomycincinpterygiumtreatment |